Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation

Pfizer

Status and phase: Completed; Phase 3; Phase 2

Conditions: Ejaculation

Treatments: Drug: UK-390,957

Study type: Interventional

Funder types: Industry

Identifiers

NCT00143117

A3871022

Details and patient eligibility

About

To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Premature ejaculation as defined by DSM-IV

Exclusion criteria

• History of erectile dysfunction

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind